Stockreport

New Studies Highlight Activity of XERAVA™ Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens

TETRAPHASE PHARMACEUTICALS INC  (TTPH) 
Last tetraphase pharmaceuticals inc earnings: 3/11 09:29 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.tphase.com/investor-relations
PDF ­ Additional Data Points to Potential of XERAVA to Treat Carbapenem-Resistant, Multidrug-Resistant Escherichia Coli ­ ­TP-6076 Demonstrates In Vivo Efficacy in Murine Lu [Read more]